Defining the role of antiandrogens in the treatment of prostate cancer
- 31 January 1996
- Vol. 47 (1) , 85-89
- https://doi.org/10.1016/s0090-4295(96)80014-8
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Severe Reversible Neutropenia Following Treatment of Prostate Cancer with FlutamideJournal of Urology, 1994
- Fatal and Nonfatal Hepatotoxicity Associated with FlutamideAnnals of Internal Medicine, 1993
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- Monotherapy with Nilutamide, A Pure Nonsteroidal Antiandrogen, in Untreated Patients with Metastatic Carcinoma of the ProstateJournal of Urology, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Cause-Specific Actuarial Survival Analysis: A Useful Method for Reporting Survival Data In Men with Clinically Localized Carcinoma of the ProstateJournal of Urology, 1989
- Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological GroupJournal of Urology, 1986
- Flutamide Therapy for Advanced Prostatic Cancer: a Phase II StudyBritish Journal of Urology, 1985
- Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapyCancer, 1984